DeSimone Jill 4
4 · Praxis Precision Medicines, Inc. · Filed Jun 26, 2026
Research Summary
AI-generated summary of this filing
Praxis (PRAX) Director Jill DeSimone Exercises Options & Sells Shares
What Happened
Jill DeSimone, a director of Praxis Precision Medicines (PRAX), exercised a total of 11,600 option shares on June 24, 2026 (8,566 shares at $44.25 and 3,034 shares at $147.30; total exercise cost $825,954) and sold those 11,600 shares in multiple open‑market transactions the same day for aggregate proceeds of $3,611,334 (weighted‑average sale price ≈ $311.32). Net cash proceeds from the exercise-and-sale were roughly $2.79M. The options cited were fully vested as of May 23, 2025 and June 5, 2025.
Key Details
- Transaction date: June 24, 2026; Form 4 filed June 26, 2026 (timely filing).
- Exercise details: 8,566 shares @ $44.25 ($379,046) and 3,034 shares @ $147.30 ($446,908).
- Sales: 11,600 shares sold across multiple trades for $3,611,334 (per‑lot weighted average prices/ranges noted in filing footnotes; overall avg ≈ $311.32).
- Footnotes: Sales were effected pursuant to a Rule 10b5‑1 trading plan adopted March 25, 2026 (F1). Several footnotes (F2–F12) provide per‑trade price ranges; F13 and F14 note the options were fully vested prior to exercise.
- Shares owned after the reported transactions: not specified in the provided excerpt of the filing.
- Transaction codes: M = exercise/conversion of derivative; S = open market sale.
Context
This was an exercise of vested options followed by same‑day open‑market sales (commonly referred to as a cashless exercise or exercise-and-sell). Sales under a pre‑arranged 10b5‑1 plan are routine and do not, by themselves, indicate the director’s current view of the company. The reporting person is a company director (not a 10% owner), and the filing does not present any late‑filing issues based on the dates shown.
Insider Transaction Report
Form 4
DeSimone Jill
Director
Transactions
- Exercise/Conversion
Common Stock
2026-06-24$44.25/sh+8,566$379,046→ 10,903 total - Exercise/Conversion
Common Stock
2026-06-24$147.30/sh+3,034$446,908→ 13,937 total - Sale
Common Stock
[F1]2026-06-24$301.44/sh−10$3,014→ 13,927 total - Sale
Common Stock
[F1][F2]2026-06-24$303.13/sh−120$36,375→ 13,807 total - Sale
Common Stock
[F1][F3]2026-06-24$305.31/sh−320$97,699→ 13,487 total - Sale
Common Stock
[F1][F4]2026-06-24$306.77/sh−683$209,522→ 12,804 total - Sale
Common Stock
[F1][F5]2026-06-24$308.24/sh−1,240$382,221→ 11,564 total - Sale
Common Stock
[F1][F6]2026-06-24$309.38/sh−999$309,074→ 10,565 total - Sale
Common Stock
[F1][F7]2026-06-24$310.89/sh−1,750$544,056→ 8,815 total - Sale
Common Stock
[F1][F8]2026-06-24$311.91/sh−2,854$890,203→ 5,961 total - Sale
Common Stock
[F1][F9]2026-06-24$312.83/sh−1,004$314,081→ 4,957 total - Sale
Common Stock
[F1][F10]2026-06-24$313.66/sh−504$158,086→ 4,453 total - Sale
Common Stock
[F1][F11]2026-06-24$314.90/sh−1,279$402,758→ 3,174 total - Sale
Common Stock
[F1][F12]2026-06-24$315.70/sh−837$264,245→ 2,337 total - Exercise/Conversion
Stock Option (Right to Buy)
[F13]2026-06-24−8,566→ 0 totalExercise: $44.25Exp: 2034-06-05→ Common Stock (8,566 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
[F14]2026-06-24−3,034→ 0 totalExercise: $147.30Exp: 2032-05-23→ Common Stock (3,034 underlying)
Footnotes (14)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on March 25, 2026.
- [F10]The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $313.400 to $314.000. The Reporting Person undertakes to provide upon request from the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
- [F11]The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $314.400 to $315.380. The Reporting Person undertakes to provide upon request from the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
- [F12]The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $315.590 to $316.010. The Reporting Person undertakes to provide upon request from the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
- [F13]This option was fully vested as of June 5, 2025.
- [F14]This option was fully vested as of May 23, 2025.
- [F2]The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $302.500 to $303.440. The Reporting Person undertakes to provide upon request from the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
- [F3]The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $305.000 to $305.830. The Reporting Person undertakes to provide upon request from the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
- [F4]The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $306.365 to $307.180. The Reporting Person undertakes to provide upon request from the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
- [F5]The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $307.900 to $308.870. The Reporting Person undertakes to provide upon request from the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
- [F6]The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $308.900 to $309.790. The Reporting Person undertakes to provide upon request from the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
- [F7]The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $310.340 to $311.300. The Reporting Person undertakes to provide upon request from the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
- [F8]The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $311.340 to $312.320. The Reporting Person undertakes to provide upon request from the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
- [F9]The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $312.370 to $313.280. The Reporting Person undertakes to provide upon request from the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
Signature
/s/ Alex Nemiroff, as Attorney-in-Fact|2026-06-26